Patents by Inventor Yumi Hagiwara

Yumi Hagiwara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8664221
    Abstract: The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye).
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: March 4, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masatomo Kato, Miwa Takai, Takahiro Matsuyama, Tatsuji Kurose, Yumi Hagiwara, Kenji Oki, Mamoru Matsuda, Toshiyuki Mori
  • Publication number: 20140045842
    Abstract: A method for treating a non-ocular inflammatory disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound represented by the following formula (1) or a salt thereof: R1 represents: R2 represents a lower alkyl group, a lower cycloalkyl group or an aralkyl group; R3 represents a lower alkyl group; R4, R5, R6 or R7 each represents a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a cyano group or a nitro group; m, n, p or q each represents 0, 1 or 2; in the case where m, n, p or q is 2, each of R4, R5, R6 or R7 is the same or different.
    Type: Application
    Filed: October 22, 2013
    Publication date: February 13, 2014
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masatomo KATO, Miwa Takai, Takahiro Matsuyama, Tatsuji Kurose, Yumi Hagiwara, Kenji Oki, Mamoru Matsuda, Toshiyuki Mori
  • Patent number: 8426406
    Abstract: The present invention is related to glucocorticoid receptor agonists comprised of a compound represented by formula (1) which is 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative or a salt thereof and novel pharmacological effects of the glucocorticoid receptor agonists. In the formula (1), R1 represents formula (2a), (3a), (4a) or (5a); R2 represents —(CO)—R8, —(CO)O—R9, or the like; R2—O— is substituted at the 4- or -5-position of benzene ring A; R3 represents a lower alkyl group; R4, R5, R6 or R7 represents a halogen atom, a lower alkyl group which may have a substituent, or the like; m, n, p or q represents 0, 1 or the like; R8, R9 or the like represents a lower alkyl group which may have a substituent, a lower alkenyl group, or the like.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: April 23, 2013
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masatomo Kato, Miwa Takai, Takahiro Matsuyama, Tatsuji Kurose, Yumi Hagiwara, Mamoru Matsuda, Toshiyuki Mori, Kenji Imoto, Atsuyoshi Dota
  • Publication number: 20110166151
    Abstract: The object aims to find a novel pharmacological activity of a novel 1,2,3,4-tetrahydroquinoxaline derivative which contains, as a substituent, a phenyl group having a sulfonic acid ester structure introduced therein. A compound represented by general formula (1) or a salt thereof is useful as a glucocorticoid receptor agonist, particularly as a therapeutic agent for diseases against which a glucocorticoid receptor agonist (e.g., a steroid) is believed to be effective, such as inflammatory bone/joint diseases, inflammatory ophthalmic diseases (inflammatory ophthalmic diseases in the anterior or posterior segment of an eye).
    Type: Application
    Filed: September 11, 2009
    Publication date: July 7, 2011
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Masatomo Kato, Miwa Takai, Takahiro Matsuyama, Tatsuji Kurose, Yumi Hagiwara, Kenji Oki, Mamoru Matsuda, Toshiyuki Mori
  • Publication number: 20110118260
    Abstract: The present invention is related to glucocorticoid receptor agonists comprised of a compound represented by formula (1) which is 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative or a salt thereof and novel pharmacological effects of the glucocorticoid receptor agonists. In the formula (1), R1 represents formula (2a), (3a), (4a) or (5a); R2 represents —(CO)—R8, —(CO)O—R9, or the like; R2—O— is substituted at the 4- or -5-position of benzene ring A; R3 represents a lower alkyl group; R4, R5, R6 or R7 represents a halogen atom, a lower alkyl group which may have a substituent, or the like; m, n, p or q represents 0, 1 or the like; R8, R9 or the like represents a lower alkyl group which may have a substituent, a lower alkenyl group, or the like.
    Type: Application
    Filed: May 12, 2009
    Publication date: May 19, 2011
    Applicant: SANTEN PHARMACEUTICAL CO.,LTD.
    Inventors: Masatomo Kato, Miwa Takai, Takahiro Matsuyama, Tatsuji Kurose, Yumi Hagiwara, Mamoru Matsuda, Toshiyuki Mori, Kenji Imoto, Atsuyoshi Dota